Maryland Oncology-Hematology

Silver Spring, Maryland 20904

3 studies enrolling now · 13 studies all time

What they study most

Advanced Breast Cancer, Breast Cancer, Cancer, Cancer of the Breast, Chronic Lymphocytic Leukemia (CLL), ER+ Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-positive Gastric Cancer, Male Breast Cancer, Metastatic Adenocarcinoma of the Pancreas, Metastatic Breast Cancer

Studies at this site

• A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) — Recruiting now
• Study of ORIC-944 in Patients With Metastatic Prostate Cancer — Recruiting now
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers — Recruiting now
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) — Running, not enrolling
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment — Completed
• Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer — Completed
• Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 — Stopped early
• Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma — Completed
• Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma — Running, not enrolling
• Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) — Completed
• Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) — Stopped early
• CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) — Completed